cat no | io6005
ioGlutamatergic Neurons SNCA A53T/WT
Human iPSC-derived Parkinson's disease model
ioGlutamatergic Neurons SNCA A53T/WT are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered heterozygous A53T mutation in the SNCA gene encoding the alpha-synuclein protein. These cells offer a rapidly maturing, consistent and scalable system to study Parkinson's disease (PD).
Place your order
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
Benchtop benefits
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of the alpha-synuclein mutation on cellular and molecular mechanisms and cell function.
Scalable
With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and genetically matched control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 10 days.
Cells arrive ready to plate
ioGlutamatergic Neurons SNCA A53T/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Highly characterised and defined
ioGlutamatergic Neurons SNCA A53T/WT form structural neuronal networks by day 10
ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) mature rapidly and form structural neuronal networks over 10 days, highly similar to the genetically matched control. Day 1 to 10 post thaw; 100X magnification.
ioGlutamatergic Neurons SNCA A53T/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.
Industry leading seeding density
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
Hoescht(blue)TUBB3(blue)_day4.jpg?width=604&name=bit.bio_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg)
Hoescht(blue)_day12v2.png?width=604&name=bit.bio_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png)
.png?width=604&name=Tech%20Nets%20online%20symposium%20header%20(1).png)
Cell culture hacks | human iPSC-derived glutamatergic neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
ioDisease Model Cells
ioDisease Model Cells
ioDisease Model Cells
ioDisease Model Cells
ioDisease Model Cells
ioWild Type Cells
CRISPR-Ready ioCells
ioWild Type Cells
ioWild Type Cells